Impact of the early reduction of cyclosporine on renal function in heart transplant patients: A French randomised controlled trial

Trials

Volumn 13, Issue , 2012, Pages

  Boissonnat, Pascale ^a   Gaillard, Ségolène ^b   Mercier, Catherine ^b,c   Redonnet, Michel ^d   Lelong, Bernard ^e   Mattei, Marie Françoise ^f   Mouly Bandini, Annick ^g   Pattier, Sabine ^h   Sirinelli, Agnès ⁱ   Epailly, Eric ^j   Varnous, Shaida ^k   Billes, Marc Alain ^l   Sebbag, Laurent ^a   Ecochard, René ^b,c   Cornu, Catherine ^b   Gueyffier, François ^b  

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f CHU NANCY BRABOIS   (France)

^g TIMONE HOSPITAL   (France)

^h CHU de Nantes   (France)

ⁱ UNIVERSITY HOSPITAL OF TOURS   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l HAUT LÉVÊQUE HOSPITAL   (France)

more..

Author keywords

Calcineurin inhibition; Cyclosporine A; Heart transplantation; Randomised clinical trial; Renal function

Indexed keywords

CHOLESTEROL; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TRIACYLGLYCEROL;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; COLD ISCHEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; CREATININE; CYCLOSPORINE; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84870300996     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-231     Document Type: Article

References (21)

1. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The registry of the international society for heart and lung transplantation: fifteenth official report-1998. J Heart Lung Transplant 1998, 17:656-668.
2. Fritsche. Impact of cyclosporine on the development of immunosuppressive therapy. Transplant Proc 2003, Suppl 2S:130S-134S.
3. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, Kucheryavaya AY, Rahmel AO, Hertz MI. Registry of the international society for heart and lung transplantation: twenty-sixth official adult heart transplant report-2009. J Heart Lung Transplant 2009, 28:1007-1022. 10.1016/j.healun.2009.08.014, 19782283.
4. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997, 63:664-668. 10.1097/00007890-199703150-00009, 9075835.
5. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931-940. 10.1056/NEJMoa021744, 12954741.
6. Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC, Theodore J. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995, 26:643-648. 10.1016/0272-6386(95)90602-9, 7573020.
7. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998, 66:507-515. 10.1097/00007890-199808270-00016, 9734496.
8. Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P. Calcineurin inhibitor minimization in the Symphony study: observational results 3years after transplantation. Am J Transplant 2009, 9:1876-1885. 10.1111/j.1600-6143.2009.02726.x, 19563339.
9. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009, 9:1607-1619. 10.1111/j.1600-6143.2009.02668.x, 19459794.
10. Cohen DJ, Vincenti F. A comparative open label study to evaluate graft function in de novo renal allograft recipients treated with reduced dose or standard dose cyclosporine in combination with sirolimus and corticosteroids. Am J Transplant 2003, Suppl 5:S465.
11. de Sévaux RG, Gregoor PJ, Hené RJ, Hoitsma AJ, Vos P, Weimar W, Van Gelder T, Hilbrands LB. A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. J Am Soc Nephrol 2001, 12:1750-1757.
12. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, . Sirolimus Renal Function Study Group Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002, 74:1560-1567. 10.1097/00007890-200212150-00013, 12490789, Sirolimus Renal Function Study Group.
13. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999, 68:1526-1532. 10.1097/00007890-199911270-00016, 10589950.
14. Muhlbacher F, Paczek L. An open-label study to evaluate the efficacy and safety of cyclosporine reductionin de novo renal allograft recipients receiving sirolimus: a dose comparative study. Am J Transplant 2002, Supp 3:S238.
15. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons W, First R. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006, 6:1377-1386. 10.1111/j.1600-6143.2006.01290.x, 16686761.
16. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005, 24:1710-1720. 10.1016/j.healun.2005.03.019, 16297770.
17. Ekberg H. The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporing (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [poster presentation] 2004, International Conference of the Transplantation Society (ICTS), Vienna, Austria.
18. Agence Nationale d'Accréditation et d'Evaluation en Santé [Diagnosis of adult chronic kidney failure]. Diabetes Metab 2003, 29:315-324. French, Agence Nationale d'Accréditation et d'Evaluation en Santé.
19. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 1999, 55:1878-1884. 10.1046/j.1523-1755.1999.00411.x, 10231450.
20. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant 2009, 9:1495-1499. 10.1111/j.1600-6143.2009.02678.x, 19519824.
21. Hertz MI, Aurora P, Benden C, Christie JD, Dobbels F, Edwards LB, Kirk R, Kucheryavaya AY, Rahmel AO, Rowe AW, Stehlik J. Scientific registry of the international society for heart and lung transplantation: introduction to the 2011 annual reports. J Heart Lung Transplant 2011, 30:1071-1132. 10.1016/j.healun.2011.08.002, 21962015.